Top Medical News
Pearl Toh, Yesterday
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Yesterday
N-acetylcysteine (NAC), sodium bicarbonate, ascorbic acid and statins appear to effectively prevent contrast-induced acute kidney injury in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention, according to a meta-analysis. Evidence is strongest for NAC, especially in patients requiring high-contrast doses.
Stephen Padilla, Yesterday
Researchers have recently developed a novel risk score, namely TARRACO*, based on bedside clinical variables and cardiac troponin (cTn) concentrations, which allows the precise quantification of risk for death and cardiac-related rehospitalizations at 180 days in patients with type 2 myocardial infarctions (T2MI) and myocardial injury (MI).
Dr. Joseph Delano Fule Robles, Yesterday

Experts from Hong Kong are recommending cardiac evaluation of surviving relatives and next-generation sequencing (NGS) molecular autopsy as components of forensic investigations for young victims of sudden cardiac death (SCD).

Roshini Claire Anthony, 2 days ago

An additional benefit of canagliflozin when administered to patients with type 2 diabetes (T2D) and high cardiovascular (CV) risk may be a reduced risk of stroke, according to results from the CANVAS* Program.

4 days ago
Physician-guided cessation of dual-antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) is safe in patients presenting with acute coronary syndrome, a recent study has shown.
Jairia Dela Cruz, 5 days ago
Eating foods rich in antioxidant compounds, such as the Mediterranean diet, helps protect against the risk of cardiovascular disease (CVD) mortality associated with long-term exposure to air pollution, according to data from the NIH-AARP Diet and Health Study.
Special Reports
Dr. Choo Gim Hooi, Assoc Prof. Pattarapong Makarawate, Dr. Krisada Sastravaha, 17 Dec 2018
Coronary artery disease (CAD) is a leading cause of mortality and morbidity globally and its burden is expected to increase due to the rising prevalence of risk factors such as hypertension, diabetes, and dyslipidaemia. In conjunction with the 23rd ASEAN Federation of Cardiology Congress held in Bangkok, Thailand, Menarini organized a lunch symposium and product theatre to discuss the significance of optimal medical therapy (OMT) in the management of stable CAD, with a focus on the role of ranolazine (Ranexa®).
30 Nov 2018
Despite risk factors for cardiovascular disease (CVD) being similar around the world, the burden of CVD is not uniform across nations. Furthermore, CVD-related death in low- to middle-income countries (LMICs) has increased by two-thirds in the last 30 years, and now account for a whopping 80% of global deaths due to CVD.
30 Nov 2018
Poor adherence to statin therapy is leaving many patients with dyslipidaemia at high risk of potentially life-threatening cardiovascular events. Statins are the current standard of care for reducing the risk of cardiovascular disease in these patients and for improving life expectancy, with possible economic benefits for healthcare systems too. However, many patients with dyslipidaemia are not achieving or maintaining treatment targets because they fail to stick to their prescribed statin therapy. An article co-authored by lipidologist Peter Lansberg, and published in Vascular Health and Risk Management, considers this issue and reviews approaches to overcome non-adherence.
28 Nov 2018
At the Abbott-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congres sat Hilton Kuala Lumpur, Dr Zanariah Hussein shared her insights into the important role of an emerging marker of hypercholesterolaemia, and its relationship with cardiovascular (CV) and diabetic retinopathy (DR) risks.
27 Nov 2018
Through a cardiology webcast co-hosted by Pfizer, the National Heart Association of Malaysia (NHAM), and the American College of Cardiology (ACC), Dr Ong Mei Lin, Dr Aaron D. Kugelmass and Dr Tracy Wang shared their insights into the importance of secondary prevention measures in reducing the burden of atherosclerotic cardiovascular disease (ASCVD).
21 Nov 2018
At the AstraZeneca-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congress at Hilton Kuala Lumpur, Professor Ronald Ma highlighted the role of a novel combination therapy in reducing HbA1c levels while simultaneously providing cardiovascular (CV) protection to improve patient outcomes.
Dr. Robert Giugliano, Prof. Ulrich Laufs, Prof. Gaetano De Ferrari, Prof. Naveed Sattar, 11 Oct 2018

The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.

Conference Reports
Pearl Toh, 15 Feb 2019
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Pank Jit Sin, 01 Feb 2019
Single pill combination (SPC) therapy is increasingly accepted and helps to overcome some of the problems associated with multipharmacy and compliance, says an expert. 
Rachel Soon, 31 Jan 2019

More home blood pressure (BP) and office BP measurements should be encouraged to identify otherwise hidden cases of hypertension, said an expert.

Rachel Soon, 31 Jan 2019

Despite increased availability of treatment options, hypertension and associated comorbidities remain a substantial public health concern, says an expert.

Elvira Manzano, 30 Nov 2018
In what many clinicians believed was a rare breakthrough, the prescription fish oil icosapent ethyl cut the risk of ischaemic events among statin-treated patients with high triglyceride levels and either cardiovascular disease (CVD) or diabetes in the REDUCE-IT* trial, putting fish oil on the front burner.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.
Roshini Claire Anthony, 23 Nov 2018

Individuals previously diagnosed with dilated cardiomyopathy (DCM) who are considered recovered from their condition may still need to continue treatment, with a higher rate of relapse observed among patients who discontinued versus continued therapy, according to the TRED-HF* trial findings presented at AHA 2018.

CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download